Mirati Therapeutics, Inc. (NASDAQ:MRTX)‘s stock had its “buy” rating restated by equities researchers at Oppenheimer Holdings, Inc. in a report released on Wednesday. They presently have a $18.00 target price on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s target price indicates a potential upside of 2.27% from the company’s current price.

Several other analysts have also recently issued reports on MRTX. SunTrust Banks, Inc. reissued a “buy” rating and issued a $13.00 target price on shares of Mirati Therapeutics in a research note on Thursday, October 12th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Mirati Therapeutics in a research note on Thursday, October 12th. Citigroup Inc. reissued a “buy” rating and issued a $16.00 target price (up from $8.00) on shares of Mirati Therapeutics in a research note on Tuesday, September 19th. Jefferies Group LLC set a $5.00 target price on Mirati Therapeutics and gave the stock a “hold” rating in a research note on Friday, August 4th. Finally, Zacks Investment Research raised Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $13.71.

Mirati Therapeutics (MRTX) opened at $17.60 on Wednesday. Mirati Therapeutics has a twelve month low of $2.70 and a twelve month high of $19.25.

Mirati Therapeutics (NASDAQ:MRTX) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.65) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.16. equities research analysts anticipate that Mirati Therapeutics will post -2.78 EPS for the current fiscal year.

WARNING: This piece of content was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://theolympiareport.com/2017/11/24/mirati-therapeutics-inc-mrtx-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.

In related news, major shareholder Venbio Select Advisor Llc purchased 650,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average cost of $13.00 per share, with a total value of $8,450,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Jamie Christensen sold 7,499 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total value of $104,986.00. Following the completion of the sale, the senior vice president now directly owns 10,169 shares in the company, valued at $142,366. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,544 shares of company stock worth $365,826. Insiders own 5.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Broadfin Capital LLC boosted its position in shares of Mirati Therapeutics by 19.1% in the 2nd quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock worth $9,091,000 after purchasing an additional 400,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Mirati Therapeutics by 68.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 336,667 shares of the biotechnology company’s stock worth $3,939,000 after purchasing an additional 137,104 shares in the last quarter. Sabby Management LLC boosted its position in shares of Mirati Therapeutics by 2.1% in the 2nd quarter. Sabby Management LLC now owns 255,100 shares of the biotechnology company’s stock worth $921,000 after purchasing an additional 5,365 shares in the last quarter. Royce & Associates LP boosted its position in shares of Mirati Therapeutics by 88.7% in the 2nd quarter. Royce & Associates LP now owns 251,100 shares of the biotechnology company’s stock worth $917,000 after purchasing an additional 118,063 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Mirati Therapeutics in the 1st quarter worth approximately $854,000. 59.80% of the stock is currently owned by hedge funds and other institutional investors.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.